Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19 in Relapsed/Refractory B-NHL
NCT05106907Phase 1Unknown
- Sponsor
- Fundamenta Therapeutics Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in B-cell non-Hodgkin lymphoma, sponsored by Fundamenta Therapeutics Inc. Primary endpoint: Treatment related adverse events. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05106907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106907.